In a 48-week phase 2 study, there was a weight reduction of up to 24.2% in participants who received the medication
Tirzepatide (Mounjaro, Zepbound) , another medication, falls under a class of drugs called GIP/GLP-1 dual receptor agonists
Additional information Enhanced Digital Features To view enhanced digital features for this article go to Rights and permissions Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made
What Is Glutamine and What Are Its Benefits
What Severe Health Complications are Alleged in Wegovy Lawsuits
Bloating alone is usually not serious, but persistent or severe symptoms should be assessed